Vertex Pharmaceuticals Incorporated - Product Pipeline Review - 2015
Summary
Global Markets Directs, Vertex Pharmaceuticals Incorporated - Product Pipeline Review - 2015, provides an overview of the Vertex Pharmaceuticals Incorporateds pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Vertex Pharmaceuticals Incorporateds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides brief overview of Vertex Pharmaceuticals Incorporated including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Vertex Pharmaceuticals Incorporateds human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Vertex Pharmaceuticals Incorporateds pipeline products
Reasons to buy
- Evaluate Vertex Pharmaceuticals Incorporateds strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Vertex Pharmaceuticals Incorporated in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Vertex Pharmaceuticals Incorporateds R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Vertex Pharmaceuticals Incorporated and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vertex Pharmaceuticals Incorporated
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Vertex Pharmaceuticals Incorporated and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table Of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Vertex Pharmaceuticals Incorporated Snapshot 6
Vertex Pharmaceuticals Incorporated Overview 6
Key Information 6
Key Facts 6
Vertex Pharmaceuticals Incorporated - Research and Development Overview 7
Key Therapeutic Areas 7
Vertex Pharmaceuticals Incorporated - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Vertex Pharmaceuticals Incorporated - Pipeline Products Glance 15
Vertex Pharmaceuticals Incorporated - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
Vertex Pharmaceuticals Incorporated - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Vertex Pharmaceuticals Incorporated - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Vertex Pharmaceuticals Incorporated - Drug Profiles 21
(lumacaftor + ivacaftor) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
(VX-661 + ivacaftor) 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
decernotinib 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
VX-210 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
VX-970 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
telaprevir 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
VX-803 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule to Inhibit HSP90 alpha/beta for Huntington's Disease 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules to Inhibit Protein Kinase for Tuberculosis 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
VE-465 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
VE-821 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
VE-822 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
VXc-486 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Next Generation Correctors 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecule to Antagonize CGRP Receptor for Migraine 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecule to Inhibit PI3K Gamma for Undisclosed Indications 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecules for Cancer 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecules for Multiple Sclerosis 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
VT-12008911 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Vertex Pharmaceuticals Incorporated - Pipeline Analysis 50
Vertex Pharmaceuticals Incorporated - Pipeline Products by Target 50
Vertex Pharmaceuticals Incorporated - Pipeline Products by Route of Administration 52
Vertex Pharmaceuticals Incorporated - Pipeline Products by Molecule Type 53
Vertex Pharmaceuticals Incorporated - Pipeline Products by Mechanism of Action 54
Vertex Pharmaceuticals Incorporated - Recent Pipeline Updates 55
Vertex Pharmaceuticals Incorporated - Dormant Projects 63
Vertex Pharmaceuticals Incorporated - Discontinued Pipeline Products 64
Discontinued Pipeline Product Profiles 64
ALS-2158 64
pralnacasan 64
VX-745 64
VX-759 64
VX-983 65
Vertex Pharmaceuticals Incorporated - Company Statement 66
Vertex Pharmaceuticals Incorporated - Locations And Subsidiaries 71
Head Office 71
Other Locations & Subsidiaries 71
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 73
Disclaimer 74
List Of Tables
Vertex Pharmaceuticals Incorporated, Key Information 6
Vertex Pharmaceuticals Incorporated, Key Facts 6
Vertex Pharmaceuticals Incorporated - Pipeline by Indication, 2015 9
Vertex Pharmaceuticals Incorporated - Pipeline by Stage of Development, 2015 10
Vertex Pharmaceuticals Incorporated - Monotherapy Products in Pipeline, 2015 11
Vertex Pharmaceuticals Incorporated - Combination Treatment Modalities in Pipeline, 2015 12
Vertex Pharmaceuticals Incorporated - Out-Licensed Products in Pipeline, 2015 13
Vertex Pharmaceuticals Incorporated - Out-Licensed Products/ Combination Treatment Modalities, 2015 14
Vertex Pharmaceuticals Incorporated - Pre-Registration, 2015 15
Vertex Pharmaceuticals Incorporated - Phase III, 2015 16
Vertex Pharmaceuticals Incorporated - Phase II, 2015 17
Vertex Pharmaceuticals Incorporated - Phase I, 2015 18
Vertex Pharmaceuticals Incorporated - Preclinical, 2015 19
Vertex Pharmaceuticals Incorporated - Discovery, 2015 20
Vertex Pharmaceuticals Incorporated - Pipeline by Target, 2015 51
Vertex Pharmaceuticals Incorporated - Pipeline by Route of Administration, 2015 52
Vertex Pharmaceuticals Incorporated - Pipeline by Molecule Type, 2015 53
Vertex Pharmaceuticals Incorporated - Pipeline Products by Mechanism of Action, 2015 54
Vertex Pharmaceuticals Incorporated - Recent Pipeline Updates, 2015 55
Vertex Pharmaceuticals Incorporated - Dormant Developmental Projects,2015 63
Vertex Pharmaceuticals Incorporated - Discontinued Pipeline Products, 2015 64
Vertex Pharmaceuticals Incorporated, Other Locations 71
Vertex Pharmaceuticals Incorporated, Subsidiaries 72
List Of Figures
Vertex Pharmaceuticals Incorporated - Pipeline by Top 10 Indication, 2015 8
Vertex Pharmaceuticals Incorporated - Pipeline by Stage of Development, 2015 10
Vertex Pharmaceuticals Incorporated - Monotherapy Products in Pipeline, 2015 11
Vertex Pharmaceuticals Incorporated - Combination Treatment Modalities in Pipeline, 2015 12
Vertex Pharmaceuticals Incorporated - Out-Licensed Products in Pipeline, 2015 13
Vertex Pharmaceuticals Incorporated - Pipeline by Top 10 Target, 2015 50
Vertex Pharmaceuticals Incorporated - Pipeline by Top 10 Route of Administration, 2015 52
Vertex Pharmaceuticals Incorporated - Pipeline by Top 10 Molecule Type, 2015 53
Vertex Pharmaceuticals Incorporated - Pipeline Products by Top 10 Mechanism of Action, 2015 54
